gemcitabine


Also found in: Dictionary, Wikipedia.

gemcitabine

 [jem-sit´ah-bēn]
an antineoplastic agent used in chemotherapy for pancreatic adenocarcinoma and non–small cell lung carcinoma; administered by intravenous infusion as the hydrochloride salt.

gemcitabine

Gemzar Oncology An IV antimetabolic antineoplastic used with cisplatin for inoperable non-small cell lung CA, and as a single agent for inoperable pancreas CA Side effects ↓ WBCs and platelets; ↑ liver enzymes; 10% discontinued medication due to flu-like Sx, N&V, rash. See Cisplatin. Cf 5-FU.

gemcitabine

A CYTOTOXIC anticancer drug. A brand name is Gemzar.
References in periodicals archive ?
In comparison, Figure 2 shows that treatment of PANC-1 cells with gemcitabine increased the percentage of cells in S phase to 60.1 [+ or -] 6.0% and reduced the percentage in the G0/G1 phase to 28.7 [+ or -] 4.2%.
"The low doses of the extract greatly boosted the effectiveness of gemcitabine. We also found that lower doses of the conventional drug were needed.
Light yellow powders of platycodin D were used as testmaterial, and white crystalline powders of gemcitabine (Sigma-Aldrich, St.
Rogel Cancer Center laboratory researchers, led by Meredith Morgan, PhD, found that AZD1775 prevented pancreatic cancer from protecting itself against the effects of radiation and gemcitabine, while leaving normal cells relatively unaffected.
[UKPRwire, Thu Jul 04 2019] A recent report published by MRRSE analyzes the impact of past and present landscape on the future of the global gemcitabine HCl market.
In the human study, IVC was administered during radiation therapy while participants received ongoing treatment with gemcitabine. Fifteen subjects were enrolled in the experimental group, and 19 subjects were selected from the records of the hospital to be used as historical comparators.
Currently, CAN04 is combined with cisplatin and gemcitabine in a clinical phase IIa study in non-small cell lung cancer (NSCLC).
TUESDAY, May 8, 2018 (HealthDay News) -- Immediate post-resection intravesical installation of gemcitabine is associated with reduced recurrence over four years for patients with suspected low-grade non-muscle-invasive urothelial cancer, according to a study published in the May 8 issue of the Journal of the American Medical Association.
An alternative to temozolomide is gemcitabine, which is still under evaluation for use as a potential radiosensitizer.
Although cytotoxic chemotherapies such as doxorubicin [2-4], gemcitabine [5-7], and docetaxel [5, 8] can provide temporary benefit in some patients with metastatic leiomyosarcoma, these agents have modest clinical effectiveness [9,10].